FDA支持Aimmune的花生过敏疗法Palforzia

2019-09-14 Allan MedSci原创

美国FDA咨询委员会支持Aimmune Therapeutics公司的花生过敏疗法Palforzia(也称为AR101)的安全性。

花生过敏是对花生的食物过敏,和树坚果过敏不同。花生过敏患者的过敏症状包括痒、荨麻疹、血管性水肿、皮肤炎、流鼻涕、哮喘、腹痛、低血压、腹泻,也可能会心搏停止,可能会出现过敏性休克的症状。

美国FDA咨询委员会支持Aimmune Therapeutics公司的花生过敏疗法Palforzia(也称为AR101)的安全性。Aimmune正在寻求美国批准Palforzia,用以减少过敏反应的发生率和严重程度。FDA代表Sofia Chaudhry告诉专家组,该机构仍在考虑对Palforzia施加安全限制。Aimmune指出,它已经为Palforzia提出了各种风险管理措施,包括施用初始剂量递增方案。


原始出处:

http://www.firstwordpharma.com/node/1666344#axzz5zU18ApSM

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1933545, encodeId=a90d193354549, content=<a href='/topic/show?id=53082180ed' target=_blank style='color:#2F92EE;'>#Aimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2180, encryptionId=53082180ed, topicName=Aimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Oct 30 02:09:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941189, encodeId=2067194118975, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2292, encryptionId=3a862292cd, topicName=ALF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Oct 16 06:09:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454787, encodeId=0c1c1454e8734, content=<a href='/topic/show?id=b2dc1369347' target=_blank style='color:#2F92EE;'>#Palforzia#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13693, encryptionId=b2dc1369347, topicName=Palforzia)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d175597431, createdName=whlxd, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507090, encodeId=39c8150e0909f, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519412, encodeId=7f4b151941242, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-10-30 Homburg
  2. [GetPortalCommentsPageByObjectIdResponse(id=1933545, encodeId=a90d193354549, content=<a href='/topic/show?id=53082180ed' target=_blank style='color:#2F92EE;'>#Aimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2180, encryptionId=53082180ed, topicName=Aimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Oct 30 02:09:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941189, encodeId=2067194118975, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2292, encryptionId=3a862292cd, topicName=ALF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Oct 16 06:09:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454787, encodeId=0c1c1454e8734, content=<a href='/topic/show?id=b2dc1369347' target=_blank style='color:#2F92EE;'>#Palforzia#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13693, encryptionId=b2dc1369347, topicName=Palforzia)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d175597431, createdName=whlxd, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507090, encodeId=39c8150e0909f, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519412, encodeId=7f4b151941242, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-10-16 xiongliangxl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1933545, encodeId=a90d193354549, content=<a href='/topic/show?id=53082180ed' target=_blank style='color:#2F92EE;'>#Aimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2180, encryptionId=53082180ed, topicName=Aimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Oct 30 02:09:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941189, encodeId=2067194118975, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2292, encryptionId=3a862292cd, topicName=ALF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Oct 16 06:09:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454787, encodeId=0c1c1454e8734, content=<a href='/topic/show?id=b2dc1369347' target=_blank style='color:#2F92EE;'>#Palforzia#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13693, encryptionId=b2dc1369347, topicName=Palforzia)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d175597431, createdName=whlxd, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507090, encodeId=39c8150e0909f, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519412, encodeId=7f4b151941242, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-09-16 whlxd
  4. [GetPortalCommentsPageByObjectIdResponse(id=1933545, encodeId=a90d193354549, content=<a href='/topic/show?id=53082180ed' target=_blank style='color:#2F92EE;'>#Aimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2180, encryptionId=53082180ed, topicName=Aimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Oct 30 02:09:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941189, encodeId=2067194118975, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2292, encryptionId=3a862292cd, topicName=ALF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Oct 16 06:09:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454787, encodeId=0c1c1454e8734, content=<a href='/topic/show?id=b2dc1369347' target=_blank style='color:#2F92EE;'>#Palforzia#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13693, encryptionId=b2dc1369347, topicName=Palforzia)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d175597431, createdName=whlxd, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507090, encodeId=39c8150e0909f, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519412, encodeId=7f4b151941242, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1933545, encodeId=a90d193354549, content=<a href='/topic/show?id=53082180ed' target=_blank style='color:#2F92EE;'>#Aimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2180, encryptionId=53082180ed, topicName=Aimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Oct 30 02:09:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941189, encodeId=2067194118975, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2292, encryptionId=3a862292cd, topicName=ALF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Oct 16 06:09:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454787, encodeId=0c1c1454e8734, content=<a href='/topic/show?id=b2dc1369347' target=_blank style='color:#2F92EE;'>#Palforzia#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13693, encryptionId=b2dc1369347, topicName=Palforzia)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d175597431, createdName=whlxd, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507090, encodeId=39c8150e0909f, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519412, encodeId=7f4b151941242, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Sep 16 07:09:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-09-16 quxin068

相关资讯

FDA批准nintedanib治疗与系统性硬化症相关的间质性肺病

美国FDA周五(2019年9月6日)宣布,批准Boehringer Ingelheim的Ofev(nintedanib)治疗与系统性硬化症相关的间质性肺病(SSc-ILD),用以减慢肺功能的下降速度。该机构指出,Ofev是FDA批准的第一种SSc-ILD治疗方法。

FDA警告基因检测公司指导个性化用药的背后

近年来,越来越多证据提示精准治疗与患者遗传基因有个性化相关性。许多基因测序公司、医疗服务机构(医院和诊所)和医生,凭借一次或几次基因测序结果(不论什么测序,用什么方法),就预测哪些药对患者有效或无效,哪个人应当服用或不建议服用哪些药。

脑转移性乳腺癌的治疗进展:FDA授予NERLYNX孤儿药物指定

Puma生物制药公司近日宣布,美国FDA已授予NERLYNX®(neratinib)孤儿药物指定,用于治疗乳腺癌脑转移患者。

美国FDA已批准抗体-药物偶联物(ADC)OBI-999的IND

OBI制药公司近日宣布,美国FDA已批准其抗体-药物偶联物(ADC)OBI-999的研究性新药申请(IND),将进行I/II期临床研究。OBI计划招募患有晚期实体瘤的患者,包括胰腺癌、胃癌、结直肠癌和食道癌。

FDA已接受ONC206的研究性新药申请(IND)

Oncoceutics制药公司近日宣布,美国FDA已接受该公司的ONC206的研究新药申请(IND),允许对该化合物进行首次人体试验。

创伤性脑损伤的治疗:FDA批准了MR-301的研究性新药申请

SHINKEI是一家专注于开发治疗中枢神经系统(CNS)疾病治疗药物的制药公司,近日宣布FDA已接受MR-301治疗严重创伤性脑损伤(sTBI)的研究性新药申请(IND)。